Under a signed strategic collaboration agreement, PARI and Kamada Ltd. (TLV: KMDA) will develop Kamada's Alpha-1 Antitrypsin (AAT) liquid drug candidate for inhalation through PARI's eFlow for the treatment of AAT deficient patients.
Also known as Alpha-1 Proteinase Inhibitor (API), AAT is used for chronic replacement therapy in individuals who are AAT deficient and have an inherited form of panacinar emphysema.
Lack of AAT leads to various health problems, including significant reduction in lung function, lung inflammation, shortness of breath, and recurrent exacerbations. This leads to emphysema, which is marked by damage to the walls of the air sacs in the lungs resulting in inefficient breathing and shortness of breath.
Currently, AAT is administered as a replacement therapy in the form of weekly intravenous infusion that distributes the medication throughout the bloodstream in order to reach the lungs.
However, an inhaled treatment would offer a more targeted therapy by delivering medication directly to the lungs. The collaboration between PARI and Kamada will address this issue.
Find more details from the press release.
Comment Preview